Goodman Advisory Group LLC Reduces Position in DexCom, Inc. $DXCM

Goodman Advisory Group LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 61.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,544 shares of the medical device company’s stock after selling 11,944 shares during the period. Goodman Advisory Group LLC’s holdings in DexCom were worth $474,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Louisiana State Employees Retirement System acquired a new position in shares of DexCom in the 1st quarter valued at $2,820,000. Fifth Third Wealth Advisors LLC boosted its stake in DexCom by 7.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 5,694 shares of the medical device company’s stock worth $358,000 after purchasing an additional 394 shares during the period. OP Asset Management Ltd acquired a new stake in DexCom during the 1st quarter worth $2,541,000. Banque Cantonale Vaudoise grew its position in DexCom by 338.2% during the 1st quarter. Banque Cantonale Vaudoise now owns 30,080 shares of the medical device company’s stock worth $1,888,000 after purchasing an additional 23,216 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in DexCom by 40.2% in the first quarter. Assenagon Asset Management S.A. now owns 1,719,249 shares of the medical device company’s stock valued at $107,969,000 after purchasing an additional 492,800 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 46,694 shares of company stock worth $3,343,977. 0.28% of the stock is owned by insiders.

DexCom Stock Up 2.2%

DXCM stock opened at $70.14 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $67.65 and its 200 day moving average price is $68.08. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a market cap of $27.06 billion, a P/E ratio of 29.97, a P/E/G ratio of 1.16 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $0.32 earnings per share. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, research analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Benchmark reiterated a “buy” rating on shares of DexCom in a research note on Tuesday. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research note on Friday, May 1st. Canaccord Genuity Group set a $82.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.